Apheresis Equipment Market Size, Share & Trends Analysis Report By Product (Disposable Apheresis Kits, Devices), By Application (Renal Diseases, Hematology, Neurology, Others), By Procedure (Plasmapheresis, LDL Apheresis, Plateletpheresis, Leukapheresis, Photopheresis, Erythrocytapheresis, Others), By Technology (Membrane Filtration, Centrifugation) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Apheresis Equipment Market Size

The global apheresis equipment market size was valued at USD 3.3 billion in 2025 and is projected to grow from USD 3.61 billion in 2026 to USD 7.44 billion by 2034, registering a CAGR of 9.45% during the forecast period from 2026 to 2034. North America dominated the apheresis equipment market with a market share of 37.01% in 2025.

The apheresis equipment market is evolving steadily, driven by increasing demand for targeted blood component separation in both therapeutic and donor applications. Growth is supported by the rising incidence of autoimmune and hematological disorders, alongside the expanding use in neurology and oncology treatments. Technological advancements such as automated systems and precision separation methods are enhancing procedural efficiency and safety. The market is also influenced by the growing role of cell-based therapies, which require specialized collection techniques. However, high equipment costs and skilled workforce requirements remain key challenges. Emerging opportunities lie in portable systems and expanding plasma collection networks, which are expected to broaden access and drive future adoption globally.

By Application

The neurology segment dominated the application category with a share of 50.20% in 2025 due to the extensive use of apheresis procedures, particularly plasma exchange, in the treatment of acute and chronic autoimmune neurological disorders such as Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and myasthenia gravis. These conditions often require rapid removal of circulating antibodies and immune complexes, making apheresis a critical and frequently used therapeutic intervention. The increasing incidence of neurological autoimmune diseases and strong clinical guidelines supporting apheresis use further reinforce its dominant position.

The hematology segment is expected to grow at a CAGR of 10.78% during the forecast period, driven by the expanding application of apheresis in managing blood-related disorders such as sickle cell disease, leukemia, and thrombotic thrombocytopenic purpura. The growing adoption of therapeutic apheresis for disease management, along with increasing utilization in donor procedures like platelet and plasma collection, is contributing to this growth. Advancements in treatment protocols and rising awareness regarding early intervention are also accelerating segment expansion.

Request Customizationto receive a tailored report.

By Procedure

Plasmapheresis dominated the procedure segment with a share of 48.23% in 2025, as it is the most widely performed apheresis technique across various medical specialties, including neurology, nephrology, and immunology. Its ability to efficiently remove harmful plasma components such as autoantibodies, toxins, and immune complexes makes it a cornerstone in treating a wide range of disorders. The presence of well-established clinical protocols and their frequent use in both emergency and maintenance therapies contribute significantly to its leading position.

Leukapheresis is the fastest-growing procedure segment with a CAGR of 10.43% during the forecast period, owing to its increasing importance in oncology and advanced therapies. It plays a crucial role in collecting white blood cells for innovative treatments such as CAR-T cell therapy and other immunotherapies. The rapid growth of cell and gene therapy research, along with increasing approvals and clinical trials, is significantly driving the demand for leukapheresis procedures.

By Product

The device segment is expected to grow at a CAGR of 10.34% during the forecast period due to continuous technological advancements in apheresis equipment, including automation, improved precision, and enhanced safety features. Healthcare facilities are increasingly adopting advanced devices that offer higher efficiency, reduced procedure time, and better patient monitoring. The integration of digital interfaces and data management systems is further supporting the widespread adoption of these devices.

Disposable apheresis kits are expanding at a CAGR of 10.12% driven by the increasing volume of apheresis procedures and the growing emphasis on infection control and patient safety. Single-use kits eliminate the risk of cross-contamination and comply with stringent regulatory standards, making them essential in clinical settings. The recurring nature of demand for disposables, linked directly to procedure frequency, ensures sustained growth in this segment.

By Technology

Centrifugation technology is expected to register a CAGR of 10.88% during the forecast period, as it provides highly efficient and precise separation of blood components based on density. Its widespread use in modern automated apheresis systems, along with its ability to handle complex and high-volume procedures, makes it the preferred technology in advanced healthcare settings. Continuous improvements in centrifugation systems are further enhancing performance and reliability.

Membrane filtration is expected to register a CAGR of 10.28% during the forecast period, supported by its cost-effectiveness and simpler operational mechanism compared to centrifugation. It is particularly suitable for selective plasma separation and is widely adopted in specific therapeutic applications. Its lower infrastructure requirements and ease of use make it an attractive option in emerging markets and smaller healthcare facilities, contributing to its steady growth.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America: Market Leadership Driven by Advanced Healthcare Infrastructure and High Procedure Volume

The North America apheresis equipment market had a share of 37.01% in 2025, driven by strong reimbursement frameworks, high adoption of therapeutic apheresis, and the presence of major device manufacturers. The region benefits from a large patient pool with autoimmune and hematological disorders, along with widespread availability of specialized treatment centers. High healthcare spending per capita and continuous upgrades in hospital-based blood management systems are accelerating the procurement of technologically advanced apheresis devices.

The US apheresis equipment market is driven by increasing demand for plasma-derived therapies, rising prevalence of chronic and blood-related diseases, and a strong network of blood donation programs and clinical research initiatives. Regulatory support for advanced therapies such as stem cell and CAR-T treatments is increasing the use of apheresis procedures like leukapheresis, thereby boosting equipment demand across hospitals and specialty centers.

The Canada apheresis equipment market growth is supported by the establishment of new plasma collection centers and efforts to reduce dependency on imported plasma. Expansion of national blood services infrastructure has improved domestic plasma supply, increasing the demand for apheresis systems and related consumables. The focus on self-sufficiency in plasma collection and rising adoption of automated blood component separation technologies are key factors strengthening market penetration in the country.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific: Fastest Growth Driven by Rising Healthcare Investment and Expansion of Tertiary Care Hospitals

The Asia Pacific apheresis equipment market is expected to register a CAGR of 11.45% during the forecast period due to increasing healthcare expenditure, expanding hospital infrastructure, and a large population base with chronic and hematological disorders. The region is supported by improvements in reimbursement systems and growing awareness of advanced therapeutic procedures. Rapid urbanization and government initiatives to modernize blood transfusion services are further accelerating the adoption of apheresis technologies.

India’s apheresis equipment market is driven by the increasing prevalence of conditions such as anemia, cancer, and autoimmune diseases. Growth is supported by expansion in tertiary care hospitals, rising investments in healthcare infrastructure, and improving access to advanced treatment options. National initiatives to strengthen blood banking systems and increase voluntary blood donation are also contributing to higher demand for apheresis procedures.

The South Korea apheresis equipment market is expanding due to its highly developed healthcare system and early adoption of advanced medical technologies. Improvements in reimbursement policies for complex procedures and increasing focus on precision medicine are encouraging the use of apheresis in therapeutic and research applications. The country’s strong biotechnology and clinical research ecosystem is also supporting demand for specialized procedures such as cell collection for immunotherapies, enhancing equipment adoption.

The Japan apheresis equipment market growth is supported by its rapidly aging population, which increases the incidence of chronic and hematological diseases requiring apheresis-based treatments. The country has a well-established healthcare infrastructure and a strong emphasis on advanced medical technologies, leading to high utilization of therapeutic apheresis procedures. Continuous innovation in medical devices and strong clinical adoption of plasma exchange therapies is sustaining steady demand for apheresis equipment across hospitals and specialized treatment centers.

Competitive Landscape

The apheresis equipment market is moderately consolidated with a few global leaders holding significant shares, yet it still exhibits pockets of fragmentation due to the presence of regional and niche technology providers. Dominant players such as Terumo BCT, Fresenius Kabi, and Haemonetics leverage broad product portfolios, global distribution networks, and continuous R&D investments to maintain leadership positions. Established companies primarily compete on technological reliability, integrated device and disposable offerings, regulatory compliance, and long-term hospital partnerships, while also strengthening positions through acquisitions and collaborations. In contrast, emerging and mid-sized players focus on cost-effective systems, specialized applications like membrane filtration or niche therapeutic indications, and expansion in underserved regional markets to gain traction. The presence of multiple manufacturers across North America, Europe, and Asia, alongside ongoing product innovation and partnerships, contributes to a semi-fragmented competitive environment despite clear leadership concentration. The market in the future will be shaped by the integration of advanced separation technologies with the growing demand for plasma-derived therapies and personalized treatment applications.

List of Key and Emerging Players in Apheresis Equipment Market